Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

2230 - Levels of endogenous anti-beta-glucan IgG antibodies (ABA) predict clinical outcomes for imprime PGG: Evidence from phase 3 PRIMUS study in patients (pts) with metastatic colorectal cancer (mCRC)


10 Oct 2016


Poster display


Merrill Shum


Annals of Oncology (2016) 27 (6): 15-42. 10.1093/annonc/mdw363


M. Shum1, J.T. Beck2, J. Meyerhardt3, R. Patel4, M. Kochenderfer5, T. Crocenzi6, M. Patchen7, M.A. Gargano8, B. Ma9, J. Lowe8, J.L. Iglesias8

Author affiliations

  • 1 Oncology, Innovative Clinical Research Institute, 90603 - Whittier/US
  • 2 Medical Oncology, Highlands Oncology Group, 72703 - Fayetteville/US
  • 3 Medical Oncology, Dana Farber Cancer Institute, 02215 - Boston/US
  • 4 Medical Oncology, Comprehensive Blood and Cancer Center, 93309 - Bakersfield/US
  • 5 Medical Oncology, Blue Ridge Cancer Care, 24014 - Roanoke/US
  • 6 Medical Oncology, Providence Portland Medical Center, 97213 - Portland/US
  • 7 Research, Biothera Pharmaceuticals, 55121 - Eagan/US
  • 8 Clinical Research, Biothera Pharmaceuticals, 55121 - Eagan/US
  • 9 Biostatistics, Biothera Pharmaceuticals, 55121 - Eagan/US


Abstract 2230


Imprime PGG (I) is a yeast-derived beta-glucan PAMP administered systemically. It binds endogenous ABA to form immune complexes opsonized by complement, which trigger immune cell activation. Combination Ph 2 trials with monoclonal antibodies (mAbs) in over 300 cancer pts have shown increased clinical benefit, including PFS and OS, enhanced in ABA+ patients.


PRIMUS was a Ph 3, open-label, multi-center randomized study of cetuximab + Imprime PGG in 3rd line K-RAS wild type mCRC pts. 217 pts were randomized 2:1 to doublet vs. singlet. Cetuximab (Erbitux®) (E) was given as per package insert and I at 4mg/kg, IV, over 2 h, weekly. Pts were treated until progression (by RECIST 1.1). Primary endpoint was OS in the Intent to Treat (ITT) population. Secondary endpoints included PFS, ORR, Time to Response (TTR), and Response Duration (RD). Translational prospective analyses included relationship of ABA levels with clinical outcomes in the evaluable population.


140 pts were randomized to I + E and 77 to E. The study closed early due to low accrual. Median OS in the ITT population was 15.1 mo. for E and 10.7 mo. for I + E. (log-rank p = 0.047). Post-progression therapy was higher for E (58%) than for I + E (46%). ORR was 10% for E and 7% for I + E (p = 0.45). TTR was shorter for I + E (1.41 mo.) than for E (2.58 mo., log-rank p = 0.03). RD was longer for I + E (7.20 mo.) than for E (4.21 mo. (log rank p = 0.36). There was no difference in PFS [4.07 mo. for I + E and 4.11 mo. for E (log-rank p = 0.11)]. Correlative analysis of OS and PFS with ABA levels showed that pts with baseline IgG ABA of >35 µg/mL, when compared to those with


I + E did not improve OS or PFS vs. E alone. Levels of IgG ABA >35 µg/mL correlated with a statistically significant increase in PFS and OS in pts receiving I+ E, but not in those receiving E alone. Further validation studies of this Imprime PGG-specific biomarker and its correlation with clinical outcomes are warranted.

Clinical trial identification


Legal entity responsible for the study

Biothera Pharmaceuticals


Biothera Pharmaceuticals


M. Patchen, M.A. Gargano, B. Ma, J. Lowe, J.L. Iglesias: Employee of Biothera Pharmaceuticals and receives stock options as part of her compensation. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings